Merrimack Pharma (MACK) Tops Q2 EPS by 10c

Merrimack Pharma (NASDAQ: MACK) reported Q2 EPS of ($0.21), $0.10 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $36.6 million versus the consensus estimate of $17.57 million.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c